Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » The Scan » In Two

In Two

Jan 11, 2021

Bluebird Bio is splitting into two companies, one focused on rare diseases and the other on cancer drugs, according to the Wall Street Journal.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

More to Mix and Match

A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.

National Academy of Sciences May Expel Members

According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.

Nucleic Acids Research Papers on DNA-Bound Proteins, Transcriptional Activation, More

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

Pause Recommended

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

What's Popular?

In Business News

  1. Benchling Raises $200M in Series E Funding Round

  2. With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

    Premium

  3. Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

  4. Invitae, PCT Therapeutics, Genome Medical Partner to Offer Genetic Testing for Cerebral Palsy

  5. DiaSorin to Acquire Luminex for $1.8B

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.